Daily Archives: June 22, 2021
[Preprint] Rapid displacement of SARS-CoV-2 variant B.1.1.7 (Alpha) by B.1.617.2 (Delta) and P.1 (Gamma) in the United States.
22 Jun, 2021 | 10:12h | UTCRapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in the United States – medRxiv
Commentary on Twitter
???Preprint
?B.1.617.2 Delta and P.1 are growing faster than B.1.1.7 & B.1.617.2 is growing faster than P.1 in the US
?B.1.617.2 will soon be the dominant variant in the US
?B.1.617.2 is growing more rapidly in counties with lower vaccination rateshttps://t.co/6Rf3p5N4ed pic.twitter.com/sVzyQRXn12— Antibiotic Steward ???Bassam Ghanem (@ABsteward) June 22, 2021
Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.
22 Jun, 2021 | 10:08h | UTCIvermectin is the new hydroxychloroquine, take 2 – Science-Based Medicine
Related: [Preprint] Meta-analysis of RCT: Ivermectin for the treatment of COVID-19 – no effect on all-cause mortality, length of stay, or viral clearance AND M-A: Prophylaxis against Covid-19: 1 – no benefit from Hydroxychloroquine; 2 – as studies on ivermectin so far have been small, it remains very uncertain whether ivermectin reduces SARS-CoV-2 infection AND Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials AND EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomized clinical trials AND FDA: Why you should not use Ivermectin to treat or prevent COVID-19 AND RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19 AND NIH Guideline Statement: “there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19” AND Video (5min): Ivermectin for COVID-19 | A Doctor Explains
Perspective | COVID-19: The rise and rise of Delta.
22 Jun, 2021 | 10:10h | UTCCOVID-19: The rise and rise of Delta – Sciblogs
2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis.
22 Jun, 2021 | 09:58h | UTC2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis – The Lancet Neurology (free registration required)
Commentary on Twitter
ONLINE FIRST: The 2021 MAGNIMS–CMSC–NAIMS international consensus recommendations on MRI in patients with multiple sclerosis provide updated guidance on how and when to use MRI for diagnosis, prognosis, and treatment monitoring of multiple sclerosishttps://t.co/bLnRo40tgw
— The Lancet Neurology (@TheLancetNeuro) June 15, 2021
Guidelines for reporting trial protocols and completed trials modified due to the COVID-19 pandemic and other extenuating circumstances: The CONSERVE 2021 Statement.
22 Jun, 2021 | 10:04h | UTC
Commentaries on Twitter
CONSERVE offers guidance that could help improve the transparency, quality, and completeness of reporting important modifications to trials in extenuating circumstances https://t.co/IiWgs7dtpQ
— JAMA (@JAMA_current) June 21, 2021
Did your clinical trial require modification due to #COVID19? Check out these reporting guidelines in @JAMA_current. https://t.co/Oy21gmrRlN
— Sherry Pagoto (@DrSherryPagoto) June 21, 2021
Case report: Multisystem inflammatory syndrome in an adult after SARS-CoV-2 infection.
22 Jun, 2021 | 10:04h | UTC
AGS publishes updated AGS Minimum Geriatrics Competencies for Graduating Medical Students.
22 Jun, 2021 | 09:59h | UTCNews release: AGS publishes updated AGS Minimum Geriatrics Competencies for Graduating Medical Students – American Geriatrics Society
Recommendations: Minimum Geriatric Competencies for Medical Students
Study shows overuse of levothyroxine in patients with subclinical hypothyroidism despite evidence of no benefit.
22 Jun, 2021 | 09:57h | UTCLevothyroxine Use in the United States, 2008-2018 (free for a limited period)
Editorial: Overuse of Levothyroxine in Patients With Subclinical Hypothyroidism: Time to “Leve”-Out-Thyroxine – JAMA Internal Medicine (free for a limited period)
Related: RCT: Levothyroxine does not reduce the risk of developing depressive symptoms in older adults with subclinical hypothyroidism (studies and guidelines on the subject)
Guideline synopsis: management of blood pressure in patients with chronic kidney disease not receiving dialysis.
22 Jun, 2021 | 10:00h | UTCOriginal guideline: KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease
Commentary: Guideline issued on blood pressure management in CKD – ACP Internist
Expert analysis: the ever-growing role of coronary artery calcium in primary prevention.
22 Jun, 2021 | 09:54h | UTC
Commentary on Twitter
New ACC Expert Analysis: The Ever-Growing Role of Coronary Artery Calcium in Primary Prevention.
More: https://t.co/GSsEqkoMbi @miguelcainzos23 @rblument1 @AndyGagel #ASCVD #cvPrev pic.twitter.com/7cUOAIArz9
— American College of Cardiology (@ACCinTouch) June 22, 2021